Top

Published in:

11-06-2022 | Lymphoma | Original Article

Magnetic resonance imaging of methotrexate-related lymphoproliferative disorder with a chief complaint of oral symptoms

Authors: Ami Kuribayashi, Sakurako Kawashima, Kou Kayamori, Junichiro Sakamoto, Hiroshi Tomisato, Hiroshi Watanabe, Tohru Kurabayashi

Published in: Oral Radiology | Issue 2/2023

Abstract

Objectives

To determine the magnetic resonance imaging (MRI) features of methotrexate-related lymphoproliferative disorder (MTX-LPD) in the oral cavity of a patient with a chief complaint of oral symptoms.

Methods

We included six patients who visited our hospital between November 2014 and November 2019, histopathologically diagnosed with MTX-LPD. All images were examined using 3 T MRI and reviewed by two radiologists.

Results

Masses were detected in five cases; all masses demonstrated signal hypointensity and homogeneous signal hyperintensity on T1- and T2-weighted images with fat suppression. Homogeneous enhancement with fat suppression was evident on post-contrast T1-weighted imaging. We performed dynamic contrast-enhanced MRI in three cases and observed early enhancement with a low washout ratio pattern in all cases. Four patients underwent diffusion-weighted MRI and revealed low mean apparent diffusion coefficient (ADC) of 0.57 (range 0.5–0.65) × 10^–3 mm²/s.

Conclusions

We reported on the imaging characteristics of six rare cases of MTX-LPD in the oral cavity. Homogeneous hyperintensity on fat-suppressed T2-weighted images and low ADC values are possible features of MTX-LPD. Moreover, MTX-LPD can be differentiated from other carcinomas in the oral cavity.

Ishida M, Hodohara K, Yoshii M, Okuno H, Horinouchi A, Nakanishi R, et al. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis. Int J Clin Exp Pathol. 2013;6:2237–41.PubMedPubMedCentral

Romão VC, Canhão H, Fonseca JE. Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic dmards? BMC Med. 2013;11:17. https://doi.org/10.1186/1741-7015-11-17.CrossRefPubMedPubMedCentral

Horie N, Kawano R, Kaneko T, Shimoyama T. Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis. Aust Dent J. 2015;60:408–11. https://doi.org/10.1111/adj.12235.CrossRefPubMed

Sce HN, Jaffe ES, Pileri SA, Stein H, Thiele J, Swerdlow VJW. WHO classif tumors hematopoietic lymphoid tissues. Lyon: IRAC Publication; 2008.

Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943–9. https://doi.org/10.1200/JCO.1996.14.6.1943.CrossRefPubMed

Furukawa S, Oobu K, Moriyama M, Kawano S, Sako S, Hayashida JN, et al. Oral methotrexate-related lymphoproliferative disease presenting with severe osteonecrosis of the jaw: a case report and literature review. Intern Med. 2018;57:575–81. https://doi.org/10.2169/internalmedicine.8946-17.CrossRefPubMed

Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 1991;18:1741–3.PubMed

Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909–15. https://doi.org/10.1182/blood.v99.11.3909.CrossRefPubMed

Kamel OW, van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein–Barr virus and other features associated with immunosuppression. Hum Pathol. 1994;25:638–43. https://doi.org/10.1016/0046-8177(94)90295-x.CrossRefPubMed

10.

Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322–31.PubMed

11.

Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42:564–71. https://doi.org/10.3899/jrheum.140533.CrossRefPubMed

12.

Kojima M, Itoh H, Hirabayashi K, Igarashi S, Tamaki Y, Murayama K, et al. Methtrexate-associated lymphoproliferative disorders. a clinicopathological study of 13 Japanese cases. Pathol Res Pract. 2006;202:679–85.CrossRefPubMed

13.

Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8. https://doi.org/10.1111/ejh.12116.CrossRefPubMed

14.

Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405–31. https://doi.org/10.1146/annurev.immunol.15.1.405.CrossRefPubMed

15.

Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114:154–63. https://doi.org/10.1016/j.clim.2004.09.001.CrossRefPubMed

16.

Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96:1691–702. https://doi.org/10.1093/jnci/djh313.CrossRefPubMed

17.

Weiss LM, Chen YY, Liu XF, Shibata D. Epstein-Barr virus and Hodgkin’s disease. a correlative in situ hybridization and polymerase chain reaction study. Am J Pathol. 1991;139:1259–65.PubMedPubMedCentral

18.

Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma. Leuk Res. 2008;32:1837–41. https://doi.org/10.1016/j.leukres.2008.04.005.CrossRefPubMed

19.

Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, et al. Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. review of the literature. medical oncology (Northwood, London, England). Med Oncol. 2009;26:1–9.CrossRefPubMed

20.

Ichikawa Y, Sumi M, Sasaki M, Sumi T, Nakamura T. Efficacy of diffusion-weighted imaging for the differentiation between lymphomas and carcinomas of the nasopharynx and oropharynx: correlations of apparent diffusion coefficients and histologic features. AJNR Am J Neuroradiol. 2012;33:761–6. https://doi.org/10.3174/ajnr.A2834.CrossRefPubMedPubMedCentral

21.

Asaumi J, Yanagi Y, Hisatomi M, Matsuzaki H, Konouchi H, Kishi K. The value of dynamic contrast-enhanced MRI in diagnosis of malignant lymphoma of the head and neck. Eur J Radiol. 2003;48:183–7. https://doi.org/10.1016/S0720-048X(02)00347-9.CrossRefPubMed

22.

Yabuuchi H, Fukuya T, Tajima T, Hachitanda Y, Tomita K, Koga M. Salivary gland tumors: diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology. 2003;226:345–54. https://doi.org/10.1148/radiol.2262011486.CrossRefPubMed

23.

Takanashi S, Nakazato T, Aisa Y, Ito C, Arakaki H, Osada Y, et al. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders. Ann Hematol. 2018;97:1611–8. https://doi.org/10.1007/s00277-018-3327-4.CrossRefPubMed

24.

Watanabe S, Manabe O, Hirata K, Oyama-Manabe N, Hattori N, Kikuchi Y, et al. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD). BMC Cancer. 2016;16:635. https://doi.org/10.1186/s12885-016-2672-8.CrossRefPubMedPubMedCentral

Title: Magnetic resonance imaging of methotrexate-related lymphoproliferative disorder with a chief complaint of oral symptoms
Authors: Ami Kuribayashi
Sakurako Kawashima
Kou Kayamori
Junichiro Sakamoto
Hiroshi Tomisato
Hiroshi Watanabe
Tohru Kurabayashi
Publication date: 11-06-2022
Publisher: Springer Nature Singapore
Keywords: Lymphoma
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Epstein-Barr Virus
Methotrexate
Methotrexate
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: Oral Radiology / Issue 2/2023
Print ISSN: 0911-6028
Electronic ISSN: 1613-9674
DOI: https://doi.org/10.1007/s11282-022-00626-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Magnetic resonance imaging of methotrexate-related lymphoproliferative disorder with a chief complaint of oral symptoms

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2023

Analysis of image defects in digital intraoral radiography based on photostimulable phosphor plates

Quantitative analysis of masticatory muscle changes by Eichner index using diffusion-weighted imaging

Magnetic resonance imaging texture analysis for quantitative evaluation of the mandibular condyle in juvenile idiopathic arthritis

Correction to: Stiffness of tongue squamous cell carcinoma measured using strain elastography correlates with the amount of collagen fibers in the tumor

Comparing the crown and root metric properties of double-rooted and single-rooted mandibular canine teeth

Multi-parametric arterial spin labeling and diffusion-weighted imaging of paranasal sinuses masses